Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | F12 | P00748 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28799386 | 0.98 | PLAU (0.54) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL26873050 | 0.83 | CYP3A4 (0.61) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL26873036 | 0.83 | PLAU (0.48) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL199273 | 0.75 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29923403 | 0.75 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL18544822 | 0.74 | CLK1 (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL24663121 | 0.73 | CYP2A6 (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL30522769 | 0.73 | PLAU (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4797349 | 0.73 | PLAU (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL18574559 | 0.73 | NOS1 (0.35) | PLAUNOS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103145616-B | Nitrogen-containing heteroaryl compounds and the purposes in increase endogenous erythropoietin thereof | FIBROGEN INC. (US) | 2015-09-30 | — | — | CN | claimed |
| CN-103145616-A | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN INC | 2013-06-12 | — | — | CN | claimed |
| CN-118666739-A | Synthesis method of titanium-catalyzed bipyridine compound and analogue | 北京师范大学 | 2024-09-20 | — | — | CN | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024144243-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 솔루스첨단소재 주식회사 | 2024-07-04 | — | — | WO | disclosed |
| CN-117247352-A | Method for synthesizing selenized isoquinolone derivative based on photocatalysis and application | 上海陶术生物科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3925952-B1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | UNIV JOHNS HOPKINS (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023221346-A1 | ORGANOMETALLIC COMPOUND AND USE THEREOF, LIGHT-EMITTING DEVICE AND LIGHT-EMITTING APPARATUS | 吉林奥来德光电材料股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
| CN-117042766-A | Method of applying a tumor therapeutic field in combination with a therapeutic agent for treating cancer | 得克萨斯大学体系董事会 | 2023-11-10 | — | — | CN | disclosed |
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| CN-114805204-B | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2023-09-15 | — | — | CN | disclosed |
| US-5401751-A | Enzyme inhibitors for 5-lipoxygenase | ZENECA LIMITED (GB) | 1995-03-28 | — | — | US | disclosed |
| US-5283245-A | Antiinflammatory agent, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-01 | — | — | US | disclosed |
| US-5236919-A | Inhibitorsof enzyme 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0381375-B1 | HETEROCYCLIC DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-11 | — | — | EP | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793063-B2 | Condensed-cyclic compound and organic light emitting device including the same | CRY1, CRY2, CCNE2 | PLAU 3354/4885CYP2A6 2286/4885F12 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.